FOLLOWUS
Evolution of the management of colorectal cancer using integrative medicine
- Chinese Journal of Integrative Medicine Vol. 17, Issue 1, Pages: 73-79(2011)
- Affiliations：
1. Fujian Medical University,Fujian,China
2. Affiliated Union Hospital of Fujian Medical University,Fujian,China
- Author bio：
- Funds：
DOI：10.1007/s11655-011-0610-9
CLC：Published：2011，
Published Online：22 January 2011，
Scan for full text
Li, St., Chi, P. Evolution of the management of colorectal cancer using integrative medicine., Chin. J. Integr. Med. 17, 73–79 (2011). https://doi.org/10.1007/s11655-011-0610-9
Shao-tang Li, Pan Chi. Evolution of the management of colorectal cancer using integrative medicine. [J]. Chinese Journal of Integrative Medicine 17(1):73-79(2011)
Li, St., Chi, P. Evolution of the management of colorectal cancer using integrative medicine., Chin. J. Integr. Med. 17, 73–79 (2011). https://doi.org/10.1007/s11655-011-0610-9 DOI：
Shao-tang Li, Pan Chi. Evolution of the management of colorectal cancer using integrative medicine. [J]. Chinese Journal of Integrative Medicine 17(1):73-79(2011) DOI： 10.1007/s11655-011-0610-9.
摘要
Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. In recent years
the development of new and effective management options
such as fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)
total mesorectal excision (TME) and monoclonal antibody novel “targeted” therapies has led to a considerable improvement in the outcome of this disease. In China
studies on CRC using integrative medicine (IM) have made remarkable progress. We therefore review the recent developments in CRC treatment through IM and Western medicine
including research studies such as the exploitation of Chinese herbs for the disruption of the tumor cell cycle or inhibition of tumor cell proliferation
induction of tumor cell apoptosis
improvement of the immune system
and the curative effect of chemotherapy. We also examine clinical studies such as those on special prescriptions and medicines and IM in anti-cancer therapy. Particularly
we analyze the advantages and disadvantages of management with IM
and propose a suggestion for the management of colorectal cancer with IM
such as screening for effective prescriptions. We also analyze Chinese medicine
studying the pharmacologic mechanism of its anti-cancer effect
further strengthening the study of IM on CRC.
Abstract
Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. In recent years
the development of new and effective management options
such as fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)
total mesorectal excision (TME) and monoclonal antibody novel “targeted” therapies has led to a considerable improvement in the outcome of this disease. In China
studies on CRC using integrative medicine (IM) have made remarkable progress. We therefore review the recent developments in CRC treatment through IM and Western medicine
including research studies such as the exploitation of Chinese herbs for the disruption of the tumor cell cycle or inhibition of tumor cell proliferation
induction of tumor cell apoptosis
improvement of the immune system
and the curative effect of chemotherapy. We also examine clinical studies such as those on special prescriptions and medicines and IM in anti-cancer therapy. Particularly
we analyze the advantages and disadvantages of management with IM
and propose a suggestion for the management of colorectal cancer with IM
such as screening for effective prescriptions. We also analyze Chinese medicine
studying the pharmacologic mechanism of its anti-cancer effect
further strengthening the study of IM on CRC.
关键词
colorectal cancerIntegrative MedicineChinese herbspharmacologic mechanism
Keywords
colorectal cancerIntegrative MedicineChinese herbspharmacologic mechanism
references
Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153–165.
Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer. Cancer 2005;104:2035–2047.
Lorenz M, Staib-Sebler E, Hochmuth K, Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol 2000; 27:112–119.
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.
Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441–9442.
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (Chin) 2005;23:1011–1027.
Jain RK, Duda DG, Clark JW, Loeffler JS. et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24–40.
Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer. J Clin Oncol 2008; 26:5721–5727.
Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232–1239
Nalluri SR, Chu D, Keresztes R, Zhu XL, Wu SH. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277–2285.
Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182–2189.
Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Annals Surg Oncol 2007;14:1860–1869.
Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer. Cancer 2005;104:2035–2047.
Huang J, Chen K, Zhang W, Zhu YL. Effect of matrine on inhibiting proliferation and inducing apoptosisof human intestinum crassum carcinoma HT29 cells. Chin Tradit Herbal Drugs (Chin) 2007;38:1210–1214.
Huang J, Zhang MJ, Qiu FM. Study on inhibitory effect of matrine on cyclooxygenase-2 expression in colon cancer HT-29 cell Line. Chin J Integr Tradit West Med (Chin) 2005;5:240–243.
Liu BR, Qian XP, Zou ZY. Effects of four extracts of traditional Chinese medicinal material on the proliferation of human colon cancer moser cell line. J Nanjing Univ (Nat Sci) 2002;38:667–671.
Hu LJ, Wen B, Zhou FS, Huang HP, Huang SG. Effects of Liandai Tablet on telomer ase activity and hTERT mRNA expression in nude mice of colonic cance. Shanghai J Tradit West Med (Chin) 2008;42:71–73.
Xu G, Huang W, Zhang WM, Lai ZS, He MR, Wang YD, et al. Effect of combined use of curcumin and catechin on cyclooxygenase-2 (COX-2) mRNA in dimethylhydrazine(DMH)-induced rat colon carcinogenesis. J First Mil Med Univ (Chin) 2005;25:48–52.
Fang HM, Mei Q, Jin J, Xu JM. Puerarin inhibit the proliferation of colon cancer HT-29 cell and part of the mechanism. Shandong Med J (Chin) 2008;48:66–68.
Cui RX, Wang GJ, Shen FQ, Gao WY, Pei YX. Allicin combined with oxaliplatin affect on the HCT-8 cell growth and proliferation and its mechanism. Shandong Med J (Chin) 2009;49:10–12.
Wang CL, Guo C, Zhou Y, Wang R. In vitro and in vivo anticolorectal carcinoma activities of Zuojin Pill and its major constituents. World J Gastroenterol 2009;17:1936–1941.
Li XP, Zheng LZ, Gu JC, Ma F, Guo WJ. Effects of Shengmai Injection combined with Oxaliplatin in treatment of liver metastasisfrom colon cancer. J Shanghai Jiaotong Univ (Med Sci) 2008;28:552–555.
Zhang JR. The effect of curcumin on growth and apoptosis of human colon carcinoma cell in vitro. Chin Arch Tradit Chin Med (Chin) 2008;26:1284–1286.
Chen JX, Wang D, Wang J, Yu HB. Effects of Yiye Baijiang Zonggan Tablets on apoptosis of human colon cancer HT-29 cells. Chin Hosp Pharm J (Chin) 2007; 27:159–161.
He C, Wu T, Hu XT, Liang JH, Chen P. Tumor suppretion activity ginsenoside Rg3 combided with TRAIL gene on human colon cancer cell line HCE8693. Chin Pharm J (Chin) 2004;39:599–601.
Zhan G, Feng LY. Effect of matrine on apoptosis and Bad expression of colorectal cancer cells in vitro. Chongqing Med (Chin) 2009;38:925–927
Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807–839.
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295–307.
Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol 2006;3:668–681.
Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol 1997;9:702–708.
Wang WP, Jiang LD, Wang CJ. Inductive effects of Changantai Capsules on T and NK cells in the intestinal mucosa in the mouse model of pulmonary cancerometastasis of colorectal cancer. J Beijing Univ Tradit Chin Med (Chin) 2001;24:34–36.
Xian PZ, Kang X, Li MY, Wang F. Effect of matrinein jections on LoVo cells and its synergetic effect with 5-Fu. Chin J Exp Surg (Chin) 2005; 22:825–826.
Ji CY, Tang SY, Liu CQ. Inhibitory effect of Paeonol on the proliferation of human colocaner cell line HT-29 and its synergetic effect with chemotherapy agents. Chin J Clin Oncol 2005;32:513–515.
Han Y, Bu LM, Ji X, Liu CY, Wang ZH. Modulation of multidrug resistance by andrographolid in HCT-8/5-Fu resistant cell line. Chin J New Drugs (Chin) 2004;13:404–407.
Yang YF, Xu Y, Wu Y, Wang LP, Li Z, Zhang LZ, et al. Clinical randomized double-blinded controlled study on Quxie Capsule in reducing post-operational relapseand metastasis of colorectal cancer. Chin J Integr Tradit West Med (Chin) 2007;27:879–882.
Hou BZ, Shu XC, Zhou SP, Fang SL, Fang SL, Li XL. Effect of on basalimmunity function of post-operative patient with carcinoma of colon, J Fourth Mil Med Univ (Chin) 2008; 29:933–935.
Luo L, Yang YF, Li PH, Wu Y, Zhang JW, Wu XW, et al. Cohort study on Fuzheng Capsule and Quxie Capsule in reducing relapse and metastasis of cancer in patients with stage II and III colorectal carcinoma after operation. Chin J Integr Tradit West Med (Chin) 2006;26:677–679.
Wang WP, Wang CJ, Liu F, Jiang LD, Hu ZM, Sun WG, et al. Clinical observation of the preventive effects of ChangAnTai on postoperation metastasis of carcinoma of large intestine in 80 cases. J Beijing Univ Trait Chin Med (Chin) 2003;26:60–62.
You Jl, Zhou LY. Fuzheng Hewei Liquid medicament for treatment of large intestine cancer in 48 cases. Pharma Clin Res (Chin) 2007;15:60–62.
You JL, Zhou LY. Clinical observation of the effect of ZhaoShi WeiTiao No. 3 (WD-3) treatment of colonrectal cancer in 105 cases. Liaoning J Tradit Chin Med (Chin) 2008;36:1201–1202.
Zhou LY, SHANG ZZ, YOU JL. Clinical observation of the effect of ZhaoShi WeiTiao No. 3 (WD-3) treatment of later stage colonrectal cancer in 44 cases. Shaanxi J Tradit Chin Med (Chin) 2008; 29:1151–1152.
Zhang BN, You JL. Study of Brucea javanica oil in TACE to improve the quality of life of colorectal liver metastases. Liaoning J Tradit Chin Med (Chin) 2008;35:84–85.
Liu UX, Jiang SJ, Kuang TH, Yao YW, Yang JW. Clinical observation of Yiqi Bushen Oral Liquid to the patients with carcinoma of large intestine’s metabasis and relapse after operation. Chin Arch Tradit Chin Med (Chin) 2007;25:1072–1073.
Li HJ, Dong L, Fu SY, Li Y. Comparative study on treatment of advanced colorectal cancer by Aidi Injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone. Chin J Integr Tradit West Med (Chin) 2007;27:1086–1089.
Ma J, Wang GH, Cai DF, Fan Y, Gu XX. Clinical observation of “JianpiXiaoliu Decoction” in preventing postoperative colorectal carcinoma recurrence and metastasis. Shanghai J Tradit Chin Med (Chin) 2005;39:24–25.
Liu J, Wang WP, Zhou YY, Fang ZY, Hou FG. Observation on therapeutic effect of Jianpi Huoxue herbs combined with chemotherapy in treating post-operational colonic cancer patients. Chin J Integr Tradit West Med (Chin) 2005;25:207–209.
Hu FS, Zhang Q, Wang XM, Yang GW, Zhao WS. Clinical study of Guben Xiaoliu Capsule combined with FOLFOX4 regimen in treating advanced colorectal cancer. Chin J Integr Tradit Wat Med (Chin) 2007;14:13–14.
Li HS, Li HH, Tang ZJ. Effect of Chang’ai Kangfu Decoction on immunity in postoperational patients with large intestine cancer. Chin J Integr Tradit West Med (Chin) 2000;20:580–582.
Shen KP, Hu B Zhang H, Zhou H, Gu X, Pan CF, et al. Astragalus Injection combined IL-2 to improve the immune function of patients with colorectal cancer. Tradit Chin Med Clin Pharmacol (Chin) 2008;24:99–101.
Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am 1997;77: 27–48.
Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1 541 necropsies. J Pathol 1986;150:195–203.
Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol 2006;41:185–192.
Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol 2006;94:68–80.
Rudmik LR, Magliocco AM. Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 2005;92:347–359.
0
Views
50
Downloads
6
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
